TY - BOOK ID - 7765740 TI - Endocannabinoid regulation of monoamines in psychiatric and neurological disorders PY - 2013 SN - 1489996087 1461479398 1461479401 PB - New York : Springer, DB - UniCat KW - Cannabinoids -- Therapeutic use. KW - Medicine. KW - Mental illness -- Treatment. KW - Nervous system -- Diseases -- Treatment. KW - Neurochemistry. KW - Neurology. KW - Neurosciences. KW - Psychiatry. KW - Cannabinoids KW - Cannabis KW - Diseases KW - Receptors, G-Protein-Coupled KW - Psychiatry and Psychology KW - Therapeutics KW - Neurotransmitter Agents KW - Receptors, Cell Surface KW - Molecular Mechanisms of Pharmacological Action KW - Analytical, Diagnostic and Therapeutic Techniques and Equipment KW - Pharmacologic Actions KW - Membrane Proteins KW - Chemical Actions and Uses KW - Proteins KW - Chemicals and Drugs KW - Amino Acids, Peptides, and Proteins KW - Mental Disorders KW - Drug Therapy KW - Endocannabinoids KW - Nervous System Diseases KW - Receptors, Cannabinoid KW - Medicine KW - Health & Biological Sciences KW - Neurology KW - Therapeutic use KW - Psychopharmacology. KW - Nervous system KW - Therapeutic use. KW - Treatment. KW - Behavioral pharmacology KW - Drugs KW - Psychotropic effects KW - Biomedicine. KW - Chemotherapy KW - Pharmacology KW - Psychotropic drugs KW - Hallucinogenic drugs KW - Terpenes KW - Biochemistry KW - Neurosciences KW - Neuropsychiatry KW - Neural sciences KW - Neurological sciences KW - Neuroscience KW - Medical sciences KW - Medicine and psychology KW - Mental health KW - Psychology, Pathological KW - Neurology . UR - https://www.unicat.be/uniCat?func=search&query=sysid:7765740 AB - The past two decades have seen a tremendous growth in knowledge related to cannabinoid receptor signaling in brain.  In addition, the impact and consequences of cannabinoid modulation of monoaminergic circuits is steadily emerging demonstrating a significant interaction between these two systems in a variety of psychiatric (affective disorders) and neurological disorders (multiple sclerosis, pain). Despite increasing evidence from preclinical data suggesting that therapeutic use of cannabinoid-based drugs may outweigh any potential risks in certain serious medical conditions, the debate surrounding its widespread utility continues as regulatory concerns preclude a smooth transition of promising preclinical studies into clinical trial testing. This may persist in the near future as state and federal governments debate over regulation of medicinal applications of cannabis. Applications for medicinal cannabinoids that are already under investigation include the treatment of nausea, anorexia, neurodegeneration, inflammation, excitotoxicity and pain. The appetitive and anti-emetic properties of cannabinoids have led to the approval of their use in chemotherapy and AIDS patients.  There is growing evidence for therapeutic cannabinoid effects on inflammatory and excitotoxic cellular processes that are linked to epilepsy, Parkinson’s disease, amyotrophic lateral sclerosis, spasticity, and central nervous system injury. The chapters, herein, review and discuss current insights into the brain endocannabinoid system, cannabinoid receptor signaling on synaptic plasticity, potential therapeutic applications with a particular focus on endocannabinoid modulation of dopaminergic, noradrenergic and serotonergic circuitry. The potential for establishing cannabinoid-monoaminergic interactions as a novel target in the development of improved treatment strategies for psychiatric and neurological disorders is promising and will require future clinical studies to determine whether promising pre-clinical findings translate into new therapies. ER -